- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00266279
Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The optimal dose and schedule for the combined treatment with oxaliplatin and capecitabine have not been defined. The aim of this Phase II study is to determine the response rate of combined oxaliplatin and capecitabine treatment at a given dose and schedule in patients with Head and Neck cancer for which there is no curative treatment.
The study also aims to determine the qualitative and quantitative toxicity and reversibility of toxicity of the above combination and to evaluate any changes in performance status, quality of life, overall survival and progression-free survival.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40202
- University of Louisville, James Graham Brown Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed squamous cell cancer of Head and Neck
- Patients must have metastatic or locally recurrent disease
- Patients must have disease not curable by surgery as estimated by one of the protocol investigators, and should not be eligible for reradiation protocol or have failed reradiation protocol.
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan
- Age >18 years of age
- Life expectancy of greater than 12 weeks
- ECOG performance status 0, 1 or 2 (Karnofsky >50%; see Appendix B)
Patients must have adequate bone marrow function as defined below:
- absolute neutrophil count > 1,500
- platelets > 100,000
- hemoglobin > 8 g/dl
Patients must have adequate renal function as defined by a creatinine clearance >30 mL/min (measured or estimated by the Cockroft and Gault equation)
- Cockroft and Gault equation:
- Creatinine clearance for males =(140-age[yrs])(body wt[kg])/72(serum creatinine[mg/dL])
- Creatinine clearance for females = 0.85 x male value
Patients must have adequate liver function as defined below:
- total bilirubin 1.5x upper limit of normal
- albumin > 2.5 g/dl
- AST(SGOT) and ALT(SGPT) and Alkaline Phosphatase must be < 5 times upper limit of normal
- Patients could have received 1 or 2 previous chemotherapy regimens prior to entering the study. Patients must have recovered from acute toxicities from chemotherapy or radiotherapy administered prior to entering this study. Alopecia may not be resolved and peripheral neuropathy (grade 1) may be present.
- Patients with reproductive potential must use an adequate contraceptive method (e.g., abstinence, intrauterine device, oral contraceptives, barrier device with spermicide or surgical sterilization) during treatment and for three months after completing treatment.
- Ability to understand and willingness to sign a written informed consent document
Exclusion Criteria:
- Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-fluorouracil or oxaliplatin
- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to first treatment in this study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Patients receiving any other investigational agent(s)
- Patients with symptomatic brain metastases or actively receiving any therapy for brain metastasis (because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events)
- Active second malignancy in the last 5 years except for non-melanoma skin cancer or carcinoma-in-situ
- Clinically significant cardiac disease (e.g. congestive heart failure, New York Heart Association Class II or greater, symptomatic coronary artery disease and cardiac arrhythmias) or myocardial infarction within the last 12 months.
- If patient is unable to swallow, xeloda may be crushed per hospital policy/procedure. See attached Appendix G.
- Patients who have had an organ allograft.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnancy
- Known Hepatitis B , Hepatitis C, HIV
Inclusion of Minorities:
Members of all ethnic groups are eligible for this trial.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Treatment with Study Drugs
Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.
|
Agent, DOSE AND SCHEDULE (28-days cycle): Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21 |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Overall Response Rate
Tijdsspanne: Every two 28 day treatment cycles until subject no longer on treatment due to disease progression
|
Among the 15 patients treated, 2 (13%) achieved partial response (PR), and 5 (33%) achieved stable disease (SD), for a Overall Response Rate (ORR) of 46% measured by RECIST criteria. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Overall Response Rate (ORR)=PR+CR. |
Every two 28 day treatment cycles until subject no longer on treatment due to disease progression
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Qualitative and Quantitative Toxicity
Tijdsspanne: At study enrollment, Every two 28 day treatment cycles, and at end of treatment due to disease progression
|
Number of patients that developed common side effect of diarrhea.
|
At study enrollment, Every two 28 day treatment cycles, and at end of treatment due to disease progression
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Damian Laber, M.D., University of Louisville, James Graham Brown Cancer Center
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 153.05
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Oxaliplatin, Capecitabine
-
SanofiVoltooid
-
The Netherlands Cancer InstituteOnbekendUitgezaaide maagkanker | Adenocarcinoom van de gastro-oesofageale overgangNederland
-
Taiho Pharmaceutical Co., Ltd.Yakult Honsha Co., LTDVoltooidColorectale kankerJapan
-
Hebei Medical UniversityOnbekendMaagkanker | Lever metastaseChina
-
Universidad de LeónWervingLokaal gevorderde darmkankerSpanje
-
Wuhan Union Hospital, ChinaWervingVergevorderde maagkanker | Geavanceerde Gastro-oesofageale Junction AdenocarcinoomChina
-
SanofiVoltooidMaagkankerKorea, republiek van
-
QureBio Ltd.WervingGastro-oesofageale overgang (GEJ) AdenocarcinoomChina
-
Xijing HospitalWervingLokaal gevorderd adenocarcinoom van de maagChina
-
Kangbuk Samsung HospitalBeëindigdMaagkankerKorea, republiek van